NIH Trial of Six-Strain Universal Flu Vaccine Candidate Begins
The nanoparticle vaccine candidate, FluMos-v2, builds on its predecessor FluMos-v1 and is designed to induce antibodies against six flu strains.
The nanoparticle vaccine candidate, FluMos-v2, builds on its predecessor FluMos-v1 and is designed to induce antibodies against six flu strains.
New research reveals how cleaner air kills airborne viruses significantly quicker and why opening a window may be more important than originally thought.
In a phase 1 clinical trial, the vaccine developed by NIAID's Vaccine Research Center was safe, well-tolerated, and induced broad antibody responses that target the hemagglutinin stem.
The preclinical research demonstrated the ability of Infectimune to significantly boost CD4 T cell activity, suggesting that Infectimune-based vaccines could provide durable protection against seasonal flu and potentially emerging pandemic flu.
Read MoreThe trial will assess the safety, tolerability, and immunogenicity of the IIV4 candidate in approximately 150 healthy participants, aged 18 to 50.
Read MoreThe 40-month project may culminate in a prototype bivalent vaccine candidate that is effective against both the H5N1 and H7N9 strains of influenza, according to Access to Advanced Health Institute.
Read MoreResearchers have discovered a compound that inhibits the body’s own methyltransferase MTr1, which limits the replication of influenza viruses and may lead to the development of new treatments for the flu.
Read MoreA poll of 1,234 adults aimed to determine how many households had recently been impacted by RSV, COVID-19 or the flu and to gauge their concern about whether they’re worried about becoming ill with one of the viruses.
Read MoreBD received FDA emergency use authorization for its new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and respiratory syncytial virus (RSV).
Read MoreThe American Thoracic Society is partnering with three health systems in the US to improve adult vaccination rates.
Read MoreWith the COVID, flu and RSV tripledemic, new research spotlights the effects of COVID-19 variants and multiple viruses on young patients.
Read MoreTesting for the presence of a single immune system molecule on a nasal swab can help detect stealthy viruses not identified in standard tests.
Read MoreResearch IDs a factor responsible for inappropriate tissue regrowth after respiratory illness, pointing to a possible therapeutic target.
Read MoreResearchers show how the pH of aerosol particles changes after exhalation and how this impacts the airborne viruses in the particles.
Read MoreKids who get the flu and COVID-19 together may be in for a serious, even deadly, bout of illness, U.S. health officials suggest.
Read More